189 related articles for article (PubMed ID: 27085744)
1. [Primary amyloidosis].
González de la Calle V; García-Sanz R; Mateos MV
Med Clin (Barc); 2016 Aug; 147(3):121-6. PubMed ID: 27085744
[No Abstract] [Full Text] [Related]
2. Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation.
Havasi A; Stern L; Lo S; Sun F; Sanchorawala V
Am J Hematol; 2016 Oct; 91(10):E458-60. PubMed ID: 27356490
[No Abstract] [Full Text] [Related]
3. Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis.
Szalat R; Sarosiek S; Havasi A; Brauneis D; Sloan JM; Sanchorawala V
Leukemia; 2021 Mar; 35(3):916-919. PubMed ID: 32737434
[No Abstract] [Full Text] [Related]
4. The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.
Iwadate D; Hasegawa E; Hoshino J; Hayami N; Sumida K; Yamanouchi M; Sekine A; Kawada M; Hiramatsu R; Suwabe T; Sawa N; Yuasa M; Wake A; Fujii T; Ohashi K; Takaichi K; Ubara Y
Intern Med; 2018 Mar; 57(5):701-706. PubMed ID: 29093408
[TBL] [Abstract][Full Text] [Related]
5. [Current treatment of AL amyloidosis].
Kovacsovics T
Rev Med Suisse Romande; 2000 Oct; 120(10):771-5. PubMed ID: 11109905
[TBL] [Abstract][Full Text] [Related]
6. A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year.
Carter JP; Foard D; Rannigan L; Aliaz K; Mahmood S; Sachchithanantham S; Fontana M; Quarta C; Martinez De Azcona Naharro A; Youngstein T; Rezk T; Wechalekar A; Whelan C; Lachmann H; Hawkins P; Gillmore J; Lane T
Amyloid; 2017 Mar; 24(sup1):72-73. PubMed ID: 28434320
[No Abstract] [Full Text] [Related]
7. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Wolf RC; Kumar SK; Gertz MA
Bone Marrow Transplant; 2019 Jul; 54(7):1077-1081. PubMed ID: 30390060
[TBL] [Abstract][Full Text] [Related]
8. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
Jain T; Kosiorek HE; Kung ST; Shah VS; Dueck AC; Gonzalez-Calle V; Luft S; Reeder CB; Adams R; Noel P; Larsen JT; Mikhael J; Bergsagel L; Stewart AK; Fonseca R
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):486-492.e1. PubMed ID: 29753692
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of AL amyloidosis, current data].
Jaccard A
Rev Med Interne; 2006 Nov; 27(11):809-12. PubMed ID: 16934914
[No Abstract] [Full Text] [Related]
10. Current treatment of AL amyloidosis.
Palladini G; Merlini G
Haematologica; 2009 Aug; 94(8):1044-8. PubMed ID: 19644136
[TBL] [Abstract][Full Text] [Related]
11. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis.
Palladini G; Russo P; Nuvolone M; Lavatelli F; Perfetti V; Obici L; Merlini G
Blood; 2007 Jul; 110(2):787-8. PubMed ID: 17606766
[No Abstract] [Full Text] [Related]
12. Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis.
Freeman B; Brauneis D; Seldin DC; Quillen K; Sloan JM; Renteria AS; Shelton AC; Teschner T; Finn KT; Sanchorawala V
Bone Marrow Transplant; 2014 Oct; 49(10):1345-6. PubMed ID: 24955784
[No Abstract] [Full Text] [Related]
13. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.
Dittus C; Uwumugambi N; Sun F; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1729-1732. PubMed ID: 27296954
[TBL] [Abstract][Full Text] [Related]
14. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective.
Badar T; Hari P; Chhabra S; Dhakal B; Drobyski WR; Fenske TS; Hamadani M; Pasquini M; Saber W; Shah NN; Shaw BE; D'Souza A
Bone Marrow Transplant; 2018 Sep; 53(9):1210-1213. PubMed ID: 29679076
[No Abstract] [Full Text] [Related]
15. Myeloma care adaptations in the UK during SARS-CoV-2 pandemic: Challenges and measurable outcomes.
Djebbari F; Panitsas F; Sharpley FA; Rampotas A; Larham J; Moore S; Gooding S; Kothari J; Ramasamy K
Eur J Haematol; 2020 Nov; 105(5):662-666. PubMed ID: 32592210
[No Abstract] [Full Text] [Related]
16. Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation.
Browning S; Quillen K; Sloan JM; Doros G; Sarosiek S; Sanchorawala V
Blood; 2017 Sep; 130(11):1383-1386. PubMed ID: 28698204
[No Abstract] [Full Text] [Related]
17. Ascites in the Course of Plasma Cell Myeloma Complicated by AL Amyloidosis.
Debski J; Usnarska-Zubkiewicz L; Kapelko-Słowik K; Pawluś A; Zaleska-Dorobisz U; Kuliczkowski K
Turk J Haematol; 2018 Mar; 35(1):71-72. PubMed ID: 27531413
[No Abstract] [Full Text] [Related]
18. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.
Gertz MA
Blood Cancer J; 2018 May; 8(5):44. PubMed ID: 29795248
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies.
Bal S; Estrada-Merly N; Costa LJ; Qazilbash MH; Kumar S; D'Souza A
Blood Cancer J; 2023 Nov; 13(1):170. PubMed ID: 37968258
[No Abstract] [Full Text] [Related]
20. [Therapy options in systemic AL-amyloidosis with renal involvement].
Hetzel GR; Schneider P; Mondry A; Heering P; Heyll A; Grabensee B
Dtsch Med Wochenschr; 2000 Aug; 125(34-35):997-1002. PubMed ID: 11004911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
